CTOs on the Move

DermTech

www.dermtech.com

 
Welcome to the new era of skin cancer detection. At DermTech we bring precision to the practice of dermatology through non-invasive genomic testing. And we developed the Smart Sticker that`s making it possible. The DermTech Smart Sticker collects an RNA sample by painlessly lifting skin cells off the entire surface of a mole. This gives doctors the power to diagnose skin cancer in its earliest stages—without a scalpel, without cutting, without scarring. After collection, stickers are sent to our team of scientists in the Gene Lab, the only commercial lab to extract nucleic acids and other proteins from non-invasive skin ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.dermtech.com
  • 11099 North Torrey Pines Road Suite 100
    La Jolla, CA USA 92037
  • Phone: 858.450.4222

Executives

Name Title Contact Details
Patrick Johnson
Vice President of Information Technology and Digital Systems Profile

Funding

DermTech raised $10M on 11/01/2017
DermTech raised $65M on 03/02/2020

Similar Companies

Medarray

Medarray is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Woodside Senior Communities

Woodside Senior Communities is a Green Bay, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Professional Imaging Consultants

Professional Imaging Consultants is a Winter Springs, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ProtoKinetix

ProtoKinetix, Inc. is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP™) that dramatically enhance the therapeutic results and reduce the cost of stem cell medicine. Due to the anti-inflammatory effect of AAGP™ molecules, the Company is currently targeting the direct treatment of diseases that have a major inflammatory component.

Better Therapeutics

Better Therapeutics ("Better") is developing first-in-class prescription digital therapeutics to deliver behavioral therapy to patients. Led by an experienced team of biotechnology executives with funding from top-tier industry investors, Better expects to go public through a merger with SPAC Mountain Crest Acquisition Corp. (NASDAQ: MCAD) during the summer of 2021. Better was founded upon the realization that nearly half a trillion dollars are spent each year treating the symptoms or effects of cardiometabolic diseases while little is being done to address the behaviors that cause them. Better has created prescription software that it believes has the opportunity to fundamentally change the treatment of a broad range of cardiometabolic diseases beginning with type 2 diabetes. The team is focused on creating significant patient impact through the launch of their first product in 2023. Better is developing a portfolio of regulated software products that treat the root causes of disease, improving the health and quality of life of patients while giving providers and payers access to cost-effective digital behavior therapies.